AUDA is an inhibitor of soluble epoxide hydrolase (sEH, IC50 = 18 nM in mice). AUDA has been shown to demonstrate hypotensive effects, accompanied by an increase in urinary epoxide-to-diol ratios. At a concentration of 10 μM, AUDA is able to activate peroxisome proliferator-activated receptor α (PPARα) 3-fold, while showing no ability to affect PPARδ or PPARγ.
1. Morisseau, Christophe., et al., 2002. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochemical pharmacology. 63(9): 1599-608. PMID: 12007563
2. Fleming, Ingrid., et al., 2004. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacological research : the official journal of the Italian Pharmacological Society. 49(6): 525-33. PMID: 15026030
3. Fang, Xiang., et al., 2005. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. The Journal of pharmacology and experimental therapeutics. 314(1): 260-70. PMID: 15798002
4. Imig, John D., et al., 2005. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 46(4): 975-81. PMID: 16157792
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.